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provided it is propeBackground: The Spectrum program is used to estimate key HIV indicators for national
programmes. The purpose of the study is to describe the key updates made to Spectrum
in the last 2 years to produce the version used in the 2013 global estimates of HIV/AIDS.
Methods: The United Nations Programme on HIV/AIDS (UNAIDS) Reference Group
on Estimates, Models and Projections regularly reviews new data and information needs
and recommends updates to the methodology and assumptions used in Spectrum. The
latest data from surveys, census and special studies are used to estimate key parameter
values for countries and regions.
Results: Country-specific life tables prepared by the United National Population
Division (UNPD) have been incorporated into Spectrum’s demographic projections
replacing the model life tables used previously. This update includes revised estimates
of non-AIDS life expectancy. Incidence among all adults 15–49 years generated from
curve fitting to surveillance and survey data is now split by age using incidence rate
ratios derived from Analysing Longitudinal Population-based HIV/AIDS data on Africa
Network data for generalized epidemics. Methods for estimating the number of AIDS
orphans have been updated to include the changing effects of PMTCT and antiretroviral
therapy programmes. Procedures for estimating the number of adults eligible for
treatment have been updated to reflect the 2013 WHO guidelines. Program data on
AIDS mortality has been used to estimate prevalence trends in Argentina, Brazil and
Mexico for the 2013 estimates.
Conclusion: Spectrum was updated for the 2013 round of HIV estimates in order to
support national programmes with improved methods and data to estimating national
indicators.  2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28 (Suppl 4):S427–S434Keywords: AIDS, estimates, HIV, modelingIntroduction
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S428 AIDS 2014, Vol 28 (Suppl 4)information to produce estimates of key indicators,
including the number of people living with HIV by age
and sex, new infections, AIDS deaths, AIDS orphans, the
need for treatment [antiretroviral therapy (ART),
prophylaxis to prevent mother-to-child transmission
and cotrimoxazole prophylaxis to prevent childhood
infections], and the impact of treatment. Earlier updates
to Spectrum and Epidemic Projection Package (EPP)
have been published previously [1]. The purpose of this
study is to describe the updates to Spectrum made in the
last 2 years and used in the 2013 global estimates of HIV/
AIDS.
The Spectrum/EPP program and manuals are updated
regularly and available in multiple languages free of charge
at www.FuturesInstitute.org. Model development has
been funded primarily by United States Agency for
International Development, UNAIDS and the Bill and
Melinda Gates Foundation with technical collaboration
from UNAIDS, WHO, United Nations Children’s Fund,
United Nations Population Division (UNPD), US
Census Bureau, United Nations Population Fund, and
other organizations.Table 1. Key inputs to Spectrum estimates.
Input Source
Base year population by age and sex (1970) World Populatio
national estim
Total fertility rate, 1970–2020 WPP 2012 or n
Non-AIDS life expectancy by sex, 1970–2020 Countries with
Countries wit
from WPP 20
Spectrum esti
Migration by age and sex, 1970–2020 WPP 2012
Breastfeeding rates by age of child among HIVþ
women
Demographic a
Number of HIVþ pregnant women receiving
PMTCT, by regimen and year
National progra
Number of HIVþ adults receiving ART by sex and
year
National progra
Number of HIVþ children receiving ART by year National progra
Number of HIVþ children receiving cotrimoxazole
by year
National progra
Criteria for ART eligibility by year National progra
Progression rates by CD4þ cell count among HIVþ
adults by age group (15–24, 25–34, 35–44, 45þ)
Estimated to fit
from ALPHA
Annual probability of adult HIV-related mortality
without treatment, by CD4þ cell count and age
Estimated to fit
from ALPHA
Annual mortality among HIVþ adults on ART by
sex, age and CD4þ cell count at treatment initiation
IeDEA Consorti
Mother-to-child transmission rates by regimen
(perinatal and postnatal)
Analysis of trial
Survival of HIVþ children without treatment Analysis of chil
Effects of ART and cotrimoxazole on survival of
HIVþ children
Expert review o
Effects of HIV infection on fertility by age Analysis of data
Surveys
Surveillance data by site, year, and population group National progra
Survey data on HIV prevalence by age and sex Demographic an
Surveys, othe
Ratio of female to male prevalence Demographic an
Surveys, othe
Incidence rate ratios ALPHA Networ
ALPHA, Analysing Longitudinal Population-based HIV/AIDS data on AfricData used in spectrum HIV/AIDS
projections
The HIV estimates produced using Spectrum rely on a
number of data sources. These can be broadly categorized
as 1) program data, 2) surveillance and survey data, and 3)
global or regional epidemiological patterns. Table 1
shows the range of data inputs and the key sources.
Demographic data are provided by the UNPD or national
statistical bureaus. Other country-specific data include
program data (number of people receiving treatment or
prophylaxis) and surveillance and survey data collected
nationally. Epidemiological parameter values are based on
a variety of scientific studies including long-running
cohort studies.Demographic estimates and projections
The UNPD produces population estimates and projec-
tions for every country in the world every 2 years. The
results of the latest 2012 World Population Prospects [2]References
n Prospects (WPP) 2012 or
ates
United Nations [2]
ational estimates United Nations [2]
low levels of HIV: WPP 2012;
h high levels of HIV: Estimated
12 all-cause mortality and
mates of AIDS mortality
United Nations [2], Methods
described in this article
United Nations [2]
nd Health Surveys
m data
m data
m data
m data
m guidelines
median survival time with HIV
network
Todd [3], Marston [4]
median survival time with HIV
network
Todd [3], Marston [4]
um Yiannoutsos [5]
s Rollins [6]
d cohort data Marston [7] Stover [1]
f available studies UNAIDS [8]
from Demographic and Health Chen [9]
m surveillance reports
d Health Surveys, AIDS Indicator
r national survey
d Health Surveys, AIDS Indicator
r national survey
k Described in this article
a; ART, antiretroviral therapy.
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Fig. 1. Mortality in Malawi with and without AIDS. (a) Life
expectancy at birth in Zambia with and without AIDS
mortality. (b) Estimated number of deaths in 2003 by age
in Zambia from all causes and non-AIDS causes.are included in Spectrum and used by most national
programmes for their national estimates. Spectrum uses
the information on population size by age and sex in 1970
and fertility, mortality, and migration rates from 1970 to
2020. Previous versions of Spectrum used model life
tables to estimate non-AIDS mortality by age from
UNPD estimates of non-AIDS life expectancy at birth.
UNPD currently focuses on producing estimates of all-
cause mortality. It produces country-specific life tables for
all countries that rely on model life tables when good data
on mortality are not available and on empirical estimates
of mortality when data are available. The sources used by
UNPD to estimate all-cause mortality include: household
surveys, censuses, demographic surveillance sites, sample
registration systems, and civil registration systems. In
countries with few AIDS deaths, there will be very little
difference between all-cause and non-AIDS mortality.
However, for 34 countries (Angola, Bahamas, Belize,
Botswana, Burkina Faso, Burundi, Cameroon, Central
African Republic, Chad, Congo, Cote d’Ivoire, Djibouti,
Democratic Republic of the Congo, Equatorial Guinea,
Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea,
Guinea-Bissau, Haiti, Jamaica, Keya, Lesotho, Liberia,
Malawi, Mali, Mozambique, Namibia, Nigeria, Rwanda,
Sierra Leone, South Africa, South Sudan, Swaziland,
Thailand, Togo, Uganda, United Republic of Tanzania,
Zambia, and Zimbabwe) HIV mortality significantly
affects the age pattern of mortality.
In countries with significant AIDS mortality, we have
estimated non-AIDS mortality by determining the
trend in non-AIDS life expectancy (the life expectancy
of those who are not infected with HIV) that, when
combined with Spectrum’s estimates of AIDS deaths,
will match the all-cause mortality estimated by UNPD.
Model life tables are used to specify the age pattern of
non-AIDS mortality. For each country, we have used
the same model life table that was previously
determined by UNPD to best fit non-AIDS mortality.
(Over the past several rounds of estimates, UNPD has
been gradually moving to using country-specific life
tables for more and more countries, but through the last
round, still provided for use in Spectrum a list of the
model life table from the Coale-Demeny or United
Nations model tables that best fit the mortality pattern
in each country.) We used these model life tables and
modified life expectancy at birth on the non-AIDS life
expectancy to match the UNPD estimates of all-cause
mortality.
Figure 1a illustrates this process for Zambia. The
estimated trend in all-cause life expectancy is prepared
by UNPD based on available empirical estimates of
mortality. The trend in non-AIDS life expectancy was
calculated so that when AIDS deaths are added, the total
mortality will match the UNPD mortality estimates.
Differences in the age pattern of mortality in 2013 are
shown in Fig. 1b.Number of adults and children eligible for
antiretroviral therapy
New treatment guidelines issued by WHO in 2013 [10]
added additional categories of people eligible for
treatment. The new guidelines recommend treatment
for all HIVþ adults with CD4þ cell counts less than
500 cells/ml, and all HIVþ pregnant women, those
coinfected with tuberculosis and HIV, HIV-infected
adults with hepatitis B infection and severe liver disease,
and those in serodiscordant partnerships. For children,
eligibility is recommended for all HIVþ children up to
5 years of age and those above the age of 5 with CD4þ cell
counts below 500 cells/ml. Spectrum estimates the size of
each of these population groups as described below.(1) CD4þ cell count. Spectrum tracks new HIV infections
among adults as they progress through CD4þ categories,
starting from greater than 500 cells/ml and progressing
to 350–500, 250–349, 200–249, 100–199, 50–99, and
less than 50. Therefore, estimates of the number of
HIVþadults by CD4þ cell count are readily available to
estimate eligibility.
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Fig.
partregnant women. The current number of HIVþ
pregnant women is estimated from the age-specific
HIV prevalence among women of reproductive age,
age-specific fertility rates, and age-specific reductions in
fertility due to HIV infection [9].(3) Tuberculosis/HIV coinfections. The proportion of
HIVþ adults who are coinfected with TB is estimated
from surveys among HIV-infected populations and the
dynamics of HIV and tuberculosis. A description of the
data and methods is provided in the study by Pretorius,
et al. [11] in this supplement.(4) Serodiscordant couples. The percentage of HIVþadults
that are in stable discordant partnerships is estimated
based on data fromDemographic andHealth Survey and
analyzed by Chemaitelly, et al. [12] for 22 countries in
sub-Saharan Africa. Using these data, we calculated a
regression equation to estimate the percentage of HIVþ
adults in serodiscordant partnerships from HIV preva-
lence among all adults 15–49 years.y ¼ 44:322 e0:047 xPðR2 ¼ 0:944ÞIn this equation, y is the percentage of all HIVþ adults
that are in stable, serodiscordant partnerships and P is HIV
prevalence among adults 15–49 years. The relationship is
shown in Fig. 2. Note that this equation estimates the
percentage of all HIVþ who are in serodiscordant part-
nerships. This is different from the figures in most
Demographic and Health Survey reports that show
HIV prevalence among stable couples which are much
lower.
These methods are used in Spectrum to estimate the
number of HIVþ adults under any set of eligibility
criteria.Swaziland
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nerships versus adult HIV prevalence.Incidence rate ratios
Data from five of the longitudinal study sites that
participate in the network for Analysing Longitudinal
Population-based HIV/AIDS data on Africa (ALPHA)
[13] were used to estimate incidence rate ratios (IRR) by
5-year age group. Data were contributed from studies in
Malawi (Karonga), Tanzania (Kisesa), Zimbabwe (Man-
icaland), Uganda (Masaka, Rakai), and South Africa
(uMkhanyakude).
All these studies have repeated HIV status data based on
research blood antibody tests carried out at regular
surveys. The interval between surveys ranges from 12 to
40 months, varying by site and over time. An incident
case of HIV infection is defined as a person who tested
positive for HIV in a research test after having previously
tested negative in the study and who was resident in the
study area at the time of both tests. People who were
positive when first tested in the study (prevalent cases)
were excluded from the analysis, with the exception of
young people aged less than 20 years, who are assumed to
be negative on their 15th birthday and are included if they
were resident at the time of the previous serosurvey but
were too young to be eligible.
The date of seroconversion is unknown (interval censored)
and must be imputed. The midpoint of the seroconver-
sion interval, between last negative and first positive test
dates, is the most common assumption but this leads to a
heaping of seroconversion dates in the months that lie
midway between two survey rounds, which can perturb
estimates of incidence rates by calendar time. Thereforewe
usedmultiple imputation to assign dates of seroconversion,
randomly allocating a date within the seroconversion
interval with a constant hazard throughout the interval.
Estimates were based on 50 imputations. IRR for 5-year
age groups were estimated from a piecewise exponential
model stratified by study site and sex.
For consistency with other ALPHA analyses, person time
after the last negative HIV test was censored at the point
after which 5% of individuals may have seroconverted.
This varied by site and ranged from 2 to 5 years.
To derive a single set of IRRs for use in Spectrum, it was
necessary to pool the results from the six studies. The
Demographic Surveillance System populations are
complete enumerations of small purposely selected
populations rather than random samples, and thus, may
not be representative of wider populations. The number
of adults included in surveillance varies between sites
from about 22 000 to 81 000, which precludes pooling
unweighted individual level data. Furthermore, these
independent studies have had different histories and
fieldwork methods and are undertaken in different
epidemic settings. We therefore used random effects
meta-analysis to estimate the average of the true IRRs.
Updates to Spectrum Stover et al. S431All analysis was carried out in Stata 13. Incidence rates and
IRR between 1997 and 2012 were estimated. No single
site contributed data to that entire range and one site
(Karonga Stata, College Station, Texas, USA) contributed
data over a limited time period and therefore had no time
trend data.
Table 2 shows the number of adults aged 15–49 years
who contributed data to the incidence analysis and the
crude incidence rates between 1997 and 2012.
Table 3 gives the average IRR, based on random effects
meta-analysis, by age group and sex (baseline: 25–29-year
olds for each sex). Figure 3 shows the IRR by age group
over the three calendar periods for each sex. There has
been a dramatic decline in the IRR for 15–19-year-old
women between the late 1990s and the late 2010s such
that the incidence for the youngest women is now likely
to be appreciably lower than that in 25–29-year-old
women. There is little difference in the incidence rates of
women in their early and late 20s but incidence is lower in
women aged 30 and above.
Incidence is lower among 15–19-year-old compared
with 25–29-year-old men, and that difference has
become more pronounced over time. Incidence has
declined somewhat in 25–29–year-old men but has not
fallen to the same extent among men in their 30s and in
some sites it has risen, moving the IRR for these men
closer to 1.Estimation of AIDS orphans
Spectrum estimates the number of maternal, paternal, and
double orphans using the methods first developed by
Grassly and Timaeus [14] and later updated [15,16]. The
calculation of the number of AIDS orphans assumed
stable patterns for mother-to-child transmission, effects of
HIV infection on fertility and mortality among HIV-
infected adults and children. In recent years, the
expansion of programmes to prevent mother-to-child
transmission and antiretroviral treatment has changed
historical patterns of mortality and the fertility-inhibiting
effects of HIV infection [17,18]. Therefore, we modifiedTable 2. Data available for analysis: dates covered, number of men and w
Study
Effective date range for
incidence estimates Individuals
Karonga 2008–2010 27038
Kisesa 1997–2012 46656
Manicaland 2000–2011 60022
Masaka 1997–2012 21986
Rakai 2000–2010 63584
uMkhanyakude 2005–2012 81258the methodology for estimation of AIDS orphans to
account for these dynamics.
Maternal AIDS orphans
The number of AIDS orphans for a woman at age aˆ at
death and CD4þ cell count category i (at death if the
woman was not on ART, and at ART initiation if the
woman was on ART) was estimated as the sum of
surviving children born before infection (V0t;aˆ;i), during
infection when not on ART (V00t;aˆ;i), and, if the woman
was on ART, during infection when on ART (V000t;aˆ;i),
(Fig. 4) using,
Vt;aˆ;i ¼
Xmaxð15;aˆ17Þ
aˆ c
¼ maxðah; aˆ 17Þ
ftc;aˆc;st;c;
V0t;aˆ;i ¼
Xmaxðah;aˆ17Þ
aˆ c
¼ maxðaA; aˆ 17Þ
ftc;aˆcraˆcðpt;cs0t;c þ ð1
 pt;cÞst;cÞ; and
V
00 ¼
XmaxðaA;aˆ17Þ
aˆ c
¼ minðaˆ ; af Þ
ftc;aˆc ðpt;cs0t;c þ ð1 pt;cÞst;cÞ;
where, c is the age of child at time t, ft,a are the fertility
rates at time t in women of age a, and st;a are the
cumulative survival probability to age a at time t for
children not infected with HIV, ra are the relative
reduction in fertility rates due to HIV infection in women
at age a [9], pt,c are probability values that a child of age c at
time t had acquired HIV from vertical transmission, and s0c
are the probability values that a child infected through
vertical transmission survives to age c. Note that orphans
are defined to be children under the age of 18 who have
lost or both parents. Thus, in these equations we only
consider children who will age 17 or younger at time t.
The mother’s age at infection, ah, and age at ART
initiation, aA, are calculated as follows.We used a look-up
matrix of constant values (M) to determine age at
infection (ah). For a woman not on ART, and at age aˆ andomen contributing data and the crude HIV incidence rate by site.
Number contributing
to incidence analysis
Crude incidence rate
(/100 person-years)
Men Women Men Women
4584 5785 0.25 0.39
3830 4534 0.80 0.80
4323 6272 1.23 1.26
6034 6922 0.58 0.69
9941 12135 0.97 1.07
5841 8511 2.46 5.44
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Table 3. Incidence rate ratios for men and women by calendar period and age group. (The 25–29 age group is the reference age group).
Age group
1997–2001 2002–2007 2008–2012
IRR 95% CI IRR 95% CI IRR 95% CI
Men
15–19 0.45 0.19–1.07 0.24 0.14–0.41 0.16 0.10–0.26
20–24 0.86 0.44–1.69 0.78 0.54–1.11 0.75 0.55–1.03
25–29 1 1 1
30–34 0.91 0.42–1.98 0.69 0.45–1.05 1.04 0.67–1.62
35–39 0.67 0.25–1.76 0.71 0.46–1.11 0.89 0.60–1.32
40–44 0.86 0.38–1.93 0.76 0.43–1.33 0.62 0.38–1.01
45–49 1.25 0.11–14.60 0.53 0.25–1.11 0.64 0.26–1.56
Women
15–19 1.21 0.58–2.50 0.69 0.49–0.97 0.61 0.46–0.81
20–24 1.17 0.58–2.34 0.99 0.74–1.31 1.10 0.90–1.35
25–29 1 1 1
30–34 0.89 0.35–2.29 0.72 0.50–1.05 0.74 0.57–0.96
35–39 0.68 0.23–2.02 0.61 0.39–0.97 0.52 0.34–0.79
40–44 0.86 0.28–2.64 0.40 0.25–0.64 0.45 0.31–0.66
45–49 0.72 0.15–3.41 0.29 0.16–0.55 0.33 0.21–0.53
CI, confidence interval; IRR, incidence rate ratios.CD4þ cell count category i at death, if matrix element
mða; iÞ equals aˆ, then age at infection ah ¼ ah
aˆ;i ¼ a: To
generateM, we assumed exponentially distributed rates of
transitionmi from CD4
þ cell count category i to iþ 1 [1],0.00
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Fig. 3. Incidence rate ratios by sex, age, and time period.and estimated mða; iÞ as the average age of a person in
CD4þ count category i given age at infection equals a.
That is, mða; iÞ ¼ aþPnk¼1ðx1 þ x2 þ ::xiÞ=n, where, xi
are instances of random variables Xi expðmiÞ and n is a
large referring to sample size (we assumed n¼ 1000).
For women on ART at time of death, to estimate age at
ART initiation, we generated a constant duration-matrix
L such that the matrix-elements lðt; iÞ represent the
average duration on ART at year t for women starting
ART at CD4þ count category i, that is,
l t; ið Þ ¼
Xj¼0
t
X
8 aN
00
j;a;i 
Yj¼0
t
X
8 aD
00
j;a;i
 hn
X
8 aN
00
j;a;i
 ioX
8 aN
00
t;a;i
where, N 00t;a;i and D00t;a;i are the number of surviving
persons on ART and number of deaths, respectively, atMother’s status 
at death
Uninfected
Infected-No ART
Infected-ART
â – 17 â
Ω
Ω’
Ω’ Ω”
Ω
Ω
â – 17 âah aA
â – 17 âah aA
ah, aA, â are the mother’s age at infection,
ART initiation, and death, respectively
Fig. 4. Schematic representation of surviving orphans born
during different time periods of mother’s life based on HIV-
status of mother at time of death.
Updates to Spectrum Stover et al. S433year t among women of age a and CD4þ count category
at ART initiation of i. For women with age aˆ at death, we
approximate age at ART initiation aA ¼ aA
t;aˆ;i ¼ aˆ lðt; iÞ
and, given matrix element m a; ið Þ ¼ aˆ l t; ið Þ; approxi-
mate age at infection ah ¼ ah
aˆ;i ¼ a.
The total number of new AIDS orphans from all women
dying at time t was estimated as
Xafþ17
aˆ¼15
X
8 i
D
0 þ D00
 
Vt;aˆ;i þV0t;aˆ;i
 
þ D00V00t;aˆ;i
n o
;
where, D
0
t; aˆ; i are the number of deaths at time t in
women of age aˆ, at CD4þ cell count category i, and not
on ART, and D
00
t; aˆ; i are the number of deaths at time t
in women of age aˆ with CD4þ count category i at
ART initiation.
Paternal AIDS orphans
Similar to the method in maternal AIDS orphans, the
total number of paternal AIDS orphans were estimated as,
Xa¯fþ17
aˆ¼15
X
8 i
D¯
0 þ D¯00
 
V¯t;aˆ;i þ V¯0t;aˆ;i
 
þ D¯00V¯00t;aˆ;i
n o
;with
V¯t;aˆ;i ¼
Xmaxð15;aˆ17Þ
aˆ c
¼ maxðah; aˆ 17Þ
f¯tc;aˆc Ptc wjmð Þst;c

þPtc wþjm
 
ktc ð1 pt;cÞst;c þ pt;cs0t;c
h io
;
V¯
0
t;aˆ;i ¼
Xmaxðah;aˆ17Þ
aˆ c
¼ maxðaA; aˆ 17Þ
f¯tc;aˆc Ptc wjmþ
 
st;c

þPtc wþjmþ
 
ktc ð1 pt;cÞst;c þ pt;cs0t;c
h io
;
V¯
00 ¼
XmaxðaA;aˆ17Þ
aˆ c
¼ minðaˆ ; a¯f Þ
f¯tc;aˆc Ptc wjmþ
 
st;c

þPtc wþjmþ
 
ktc ð1 pt;cÞst;c þ pt;cs0t;c
h io
;
where, V¯t;aˆ;i, V¯
0
t;aˆ;i, and V¯
00
t;aˆ;i are the surviving children
born to men before they were infected, during infection
when not on ART, and, for men on ART, during
infection when on ART, respectively. D¯
0
t; a; i are the
number of deaths at time t in men of age a, at CD4þ cell
count category i, and not on ART, and D¯
00
t; a; i are the
number of deaths at time t in men of age awith CD4þ cell
count category i at ART initiation. As in maternal AIDS
orphans, ah and aA represent aA
t;aˆ;i (age at infection) and a
h
aˆ;i
(age at ART initiation), respectively, and were estimated
as in the case of women. PtðwsjmsÞ are the conditionalprobability of HIV status of the mother given the HIV
status of the father, which were estimated using the
procedure in [1].Adjusting incidence trends to match
program data
Trends in HIV prevalence and incidence are estimated in
Spectrum by fitting curves to surveillance and survey data
[19]. This approach is appropriate in countries that have
relatively good surveillance and survey data for the
general population as in many countries in sub-Saharan
Africa and for those countries with concentrated
epidemics with good surveillance among key populations
as in many countries in Asia. In many of these countries,
vital statistics on AIDS deaths may suffer from significant
underreporting and cannot be used in prevalence and
incidence estimation. In Latin America, HIV surveillance
is not widely implemented but vital registration of deaths
and program monitoring of HIV patients is relatively
strong. Many countries in the region have good estimates
of the numbers of deaths due to HIV/AIDS developed by
adjusting recorded AIDS deaths for misclassification of
cause of death [20]. In addition, many countries have
estimates of the number of people living with HIVand on
new HIV diagnoses based on case-report systems. Brazil
estimates the number of people living with HIV by
adding the number of people on ART and the number
known to be HIVþ but not yet started on ART, and adds
a percentage estimate of those who are HIVþ but not yet
identified based on estimates of unknown status in the
United States. Argentina adjusts data on the number
HIVþ by the proportion of AIDS deaths that occurred to
people who were not recorded as being HIV infected.
Although these estimates have some shortcomings in
many countries, they may be better indicators of the
epidemic dynamics than surveillance data. In Argentina,
Brazil, and Mexico, incidence trends based on surveil-
lance data have been modified to better match program
estimates of the number of people living with HIV, the
number of new cases of HIV, and HIV-related mortality.
In some cases, this is accomplished simply by moving the
entire incidence curve up or down. In others cases, it
involves changing the shape of the incidence curve,
particularly in the years before surveillance data began.
The incidence curve is modeled as a double logistics
function of the form:
It ¼ ½eaðtt0Þ=ð1þ eaðtt0ÞÞ
 f2a½ebðtt0Þ=ð1þ ebðtt0Þ þ bg
Where:
a¼ rate of increase at the beginning of the trend
b¼ rate of convergence to the asymptote
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Fig. 5. Incidence trends in Mexico derived from fitting to
surveillance data on prevalence by risk group and by fitting
to program data on AIDS deaths, people living with HIV and
new cases identified.t0¼ the time of the inflexion point
a¼ peak incidence value
b¼ asymptote
Changes in the parameter values were made by hand to
improve the fit to program data. In future versions of
Spectrum, we intend to automate the process of finding
the incidence curve that allows Spectrum to best fit to
program data.
An example for Mexico is provided in Fig. 5. In general,
these adjustments have resulted in incidence curves that
are lower and with flatter peaks than those based solely on
surveillance data.Conclusion
The UNAIDS Reference Group on Estimates, Models
and Projections regularly reviews the methods used to
estimate key HIV indicators and indicates areas for
improvement. The 2013 round of estimates uses new
approaches and data to improve estimates of demographic
change, the number eligible for ART, AIDS orphans, and
the age distribution of incidence.Acknowledgements
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